NCT02418689 - Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

April 30, 2021

Conditions

Metastatic Breast Cancer

Interventions

DRUG

NOV120101 (Poziotinib)

NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development

Trial Locations (7)

410-769

National Cancer Center, Goyang-si

463-707

Seoul National University Bundang Hospital, Seongnam-si

361-711

Chungbuk National University Hospital, Cheongju-si

135-710

Samsung Medical Center, Gangnam-gu

110-744

Seoul National University Hospital, Jongno-gu

120-752

Severance Hospital, Seodaemun-gu

138-736

Asan Medical Center, Songpa-gu